hu-17

HU-17 is a **novel small-molecule aromatase inhibitor** that suppresses the viability of and promotes apoptosis in ovarian cancer cells. It acts by inhibiting estrogen biosynthesis primarily through **decreasing aromatase (CYP19A1) mRNA expression**, suppressing the phosphorylation of cAMP response element-binding protein-1, and accelerating aromatase protein degradation. HU-17 does not directly inhibit aromatase enzyme activity but reduces estrogen synthesis and is being investigated for potential use in treating **estrogen-dependent cancers** such as ovarian, breast, and endometrial cancers. Its molecular effects include inhibition of the ERK pathway and reduction of estradiol levels in cancer cells. The developer or specific manufacturer is not identified in the available literature[1].